25E-NBOH

25E-NBOH (also known as 2C-E-NBOH and NBOH-2C-E) is a novel psychedelic substance of the phenethylamine class. It is related to 2C-E and NBOH series. 25E-NBOH is a relatively new substance, and little is known about its pharmacological risks or its behavioral effects.

History and usage

25E-NBOH was first synthesized by David E. Nichols as part of his research at the Purdue University. It was later studied by a team at the University of Copenhagen, who published their findings in 2014. The substance is used primarily for recreational purposes, and is known for its psychedelic effects, which include open and closed-eye visuals, time distortion, enhanced introspection, and ego loss.

Chemistry

25E-NBOH is a derivative of the 2C family of psychedelics, which are known for their complex and varied effects. It is structurally similar to other substances in the NBOH series, with the primary difference being the addition of an ethyl group to the nitrogen of the phenethylamine backbone.

Pharmacology

The pharmacology of 25E-NBOH is not fully understood. It is believed to act as a potent partial agonist for the 5-HT2A receptor, which is involved in the regulation of mood, anxiety, and perception. The substance's effects are believed to result from this activity at the 5-HT2A receptor.

Effects

The effects of 25E-NBOH can vary greatly depending on the dose, the individual's physiology, and the environment in which it's taken. Common effects include visual hallucinations, altered perception of time, enhanced introspection, and a sense of euphoria. Some users also report experiencing negative effects such as anxiety, paranoia, and uncomfortable physical sensations.

Legal status

The legal status of 25E-NBOH varies by country. In some countries, it is a controlled substance, while in others it is legal to possess and use.

See also

• 25I-NBOH
• 25C-NBOH
• 25B-NBOH
• Psychedelic drug
• Phenethylamine